| Optimizing cancer immunotherapy trials: back to basics. | |
| | |
MedLine Citation:
|
PMID: 16639707 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Attempts to raise effective immunity against cancer are benefiting from information on the nature of the immunity involved and its regulation and, perhaps, now it is time to step back and define our approach in molecular terms prior to clinical testing. Although there are immunological differences between mice and patients, results from murine studies are encouraging early 'translation' of concepts to the clinic and it is vital to take immunological principles emerging from mice into clinical vaccine design. One is the requirement to break tolerance against over-expressed self-antigens, a potentially risky procedure but necessary for several cancer targets. A study in this issue of the European Journal of Immunology attempts to do this by using xenogeneic antigens, albeit with variable outcome. The unstated goal is to activate T-cell help but this can be achieved more effectively by harnessing a predictable anti-microbial repertoire. The second issue lies in the delivery of antigen. One strategy is "prime/boost" using DNA priming and boosting with a viral vector; however, this induces blocking immunity against viral proteins, and must be used judiciously. There are other physical methods to increase immunity such as electroporation, which can itself be used in 'prime/boost' sequence. These twin problems of engagement of T-cell help and delivery of adequate antigen can now be addressed by applying immunological logic to cancer vaccines. |
| | |
Authors:
|
Freda K Stevenson; Jason Rice |
Related Documents
:
|
16461227 - Dna-designed avian igy antibodies: novel tools for research, diagnostics and therapy. 10516057 - Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vecto... 12922127 - Evaluation of protective efficacy and immune mechanisms of using a non-structural prote... 15885127 - Synergistic antibody induction by antigen-cd40 ligand fusion protein as improved immuno... 20116277 - Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy sy... 12750257 - Enhancing major histocompatibility complex class i antigen presentation by targeting an... |
Publication Detail:
|
Type: Comment; Journal Article |
Journal Detail:
|
Title: European journal of immunology Volume: 36 ISSN: 0014-2980 ISO Abbreviation: Eur. J. Immunol. Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-05-01 Completed Date: 2006-06-15 Revised Date: 2011-10-28 |
Medline Journal Info:
|
Nlm Unique ID: 1273201 Medline TA: Eur J Immunol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1070-3 Citation Subset: IM |
Affiliation:
|
Molecular Immunology Group, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton, UK. fs@soton.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antigens, Neoplasm
/
genetics*,
immunology Cancer Vaccines / immunology* Cell Adhesion Molecules / genetics*, immunology Clinical Trials as Topic Humans Immunotherapy / methods* Neoplasms / immunology, therapy* T-Lymphocytes, Cytotoxic / immunology T-Lymphocytes, Helper-Inducer / immunology Vaccines, Synthetic / immunology* |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, Neoplasm; 0/Cancer Vaccines; 0/Cell Adhesion Molecules; 0/EPCAM protein, human; 0/Vaccines, Synthetic |
| Comments/Corrections | |
Comment On:
|
Eur J Immunol. 2006 May;36(5):1337-49
[PMID:
16619291
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is long-term humoral immunity in the mucosa provided by long-lived plasma cells? A question still op...
Next Document: Surface antibacterial characteristics of plasma-modified polyethylene.